The Case Comprehensive Cancer Center

Study Reveals Factors Influencing Immune Checkpoint Inhibitor Efficacy in Metastatic Colorectal Cancer

2 months ago

• Cleveland Clinic and Moffitt Cancer Center researchers analyzed data from nearly 19,000 metastatic colorectal cancer patients, confirming immune checkpoint inhibitors significantly improve survival in MSI-H tumors compared to chemotherapy alone. • The study identified specific factors that may enhance immune checkpoint inhibitor efficacy in traditionally unresponsive MSS tumors, including high albumin levels and recent antibiotic use, potentially expanding treatment options. • Approximately 12.3% of patients with MSS tumors achieved durable responses to immune checkpoint inhibitors, suggesting the need for further research to identify biomarkers that could predict treatment success in this population.

Natera's Signatera Shows Promise in Colorectal Cancer MRD Detection and Early Detection

4 months ago

• Natera's Signatera test demonstrates strong prognostic and predictive capabilities in colorectal cancer (CRC) patients, particularly in identifying minimal residual disease (MRD). • The BESPOKE CRC study reveals that post-surgical Signatera positivity is associated with inferior outcomes in stage II and III CRC patients, with significant differences in disease-free survival. • A novel tissue-free MRD detection test from Natera shows high sensitivity and specificity, indicating its potential as a non-invasive method for MRD assessment. • Data from the CIRCULATE and PROCEED-CRC studies highlight Signatera's effectiveness in early colorectal cancer detection, achieving high sensitivity and specificity rates.

Sacituzumab Govitecan Shows Promise in Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

8 months ago

• Sacituzumab govitecan demonstrated a 41.9% overall response rate in patients with extensive-stage small cell lung cancer (ES-SCLC) who had progressed after one prior line of therapy. • The TROPiCS-03 trial data showed a manageable safety profile, consistent with previous studies of sacituzumab govitecan, with no treatment discontinuations due to adverse events. • Median overall survival was 13.6 months, and the median progression-free survival was 4.4 months, indicating a clinically meaningful benefit in this patient population. • These encouraging results have led to the initiation of a randomized phase 3 study to further evaluate sacituzumab govitecan in relapsed ES-SCLC.